CN101829216B - 一种治疗支气管炎,支气管哮喘的中药制剂制备方法及检测方法 - Google Patents
一种治疗支气管炎,支气管哮喘的中药制剂制备方法及检测方法 Download PDFInfo
- Publication number
- CN101829216B CN101829216B CN2009100147880A CN200910014788A CN101829216B CN 101829216 B CN101829216 B CN 101829216B CN 2009100147880 A CN2009100147880 A CN 2009100147880A CN 200910014788 A CN200910014788 A CN 200910014788A CN 101829216 B CN101829216 B CN 101829216B
- Authority
- CN
- China
- Prior art keywords
- solution
- medicinal material
- control medicinal
- chromatograph
- reference substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 208000030603 inherited susceptibility to asthma Diseases 0.000 title claims abstract description 6
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 5
- 238000003908 quality control method Methods 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 32
- 206010011224 Cough Diseases 0.000 claims abstract description 19
- 239000002775 capsule Substances 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 9
- 206010014561 Emphysema Diseases 0.000 claims abstract description 3
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- 238000012360 testing method Methods 0.000 claims description 42
- 239000000463 material Substances 0.000 claims description 34
- 239000013558 reference substance Substances 0.000 claims description 23
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 12
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 12
- 229960003321 baicalin Drugs 0.000 claims description 12
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 239000012567 medical material Substances 0.000 claims description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 10
- 239000000853 adhesive Substances 0.000 claims description 10
- 230000001070 adhesive effect Effects 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000019634 flavors Nutrition 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 10
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 238000004809 thin layer chromatography Methods 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 230000003760 hair shine Effects 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 241000218628 Ginkgo Species 0.000 claims description 6
- 235000011201 Ginkgo Nutrition 0.000 claims description 6
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 6
- 241000237636 Pheretima Species 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 230000005180 public health Effects 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000012085 test solution Substances 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 2
- 201000006306 Cor pulmonale Diseases 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 2
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 2
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 claims description 2
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical class O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- INCWELKXTZCRSA-UHFFFAOYSA-N ethyl acetate;methanol;hydrate Chemical compound O.OC.CCOC(C)=O INCWELKXTZCRSA-UHFFFAOYSA-N 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 2
- 229940025878 hesperidin Drugs 0.000 claims description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 235000011477 liquorice Nutrition 0.000 claims description 2
- 229930014456 matrine Natural products 0.000 claims description 2
- JWHHANVGNNWIRI-UHFFFAOYSA-N methanol phosphoric acid hydrate Chemical compound O.OC.OP(O)(O)=O JWHHANVGNNWIRI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 238000005457 optimization Methods 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 230000007012 clinical effect Effects 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000002407 reforming Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000012850 discrimination method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940126532 prescription medicine Drugs 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000005801 respiratory difficulty Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100147880A CN101829216B (zh) | 2009-03-12 | 2009-03-12 | 一种治疗支气管炎,支气管哮喘的中药制剂制备方法及检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100147880A CN101829216B (zh) | 2009-03-12 | 2009-03-12 | 一种治疗支气管炎,支气管哮喘的中药制剂制备方法及检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101829216A CN101829216A (zh) | 2010-09-15 |
CN101829216B true CN101829216B (zh) | 2011-11-16 |
Family
ID=42713538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100147880A Active CN101829216B (zh) | 2009-03-12 | 2009-03-12 | 一种治疗支气管炎,支气管哮喘的中药制剂制备方法及检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101829216B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103134883B (zh) * | 2011-11-28 | 2015-05-13 | 邯郸制药股份有限公司 | 一种药物组合物及其制剂的检测方法 |
CN102716222B (zh) * | 2012-06-14 | 2013-09-11 | 李良 | 治疗咳嗽的白果中药汤剂及制备方法 |
CN102759600A (zh) * | 2012-08-06 | 2012-10-31 | 四川逢春制药有限公司 | 苏菲咳糖浆的检测方法 |
CN103245754B (zh) * | 2013-05-15 | 2014-11-12 | 西南大学 | 改进的苦参薄层色谱鉴别方法 |
CN108240931B (zh) * | 2018-04-28 | 2019-01-25 | 重庆港宏中药材种植有限公司 | 一种治疗关节炎、痛风的中药制剂的粉碎筛选设备 |
CN109856261A (zh) * | 2018-12-29 | 2019-06-07 | 上海市儿童医院 | 一种采用hplc同时分析“穴位敷贴方”中有效成分的方法 |
-
2009
- 2009-03-12 CN CN2009100147880A patent/CN101829216B/zh active Active
Non-Patent Citations (5)
Title |
---|
华人民共和国卫生部药典委员会.喘嗽宁片.《中华人民共和国卫生部药品标准 中药成方制剂第十九册》.1998,205. * |
唐启令等.清热消炎合剂质量标准研究.《中国药业》.2003,第12卷(第12期),49. * |
姜卫中等.芩花清毒颗粒质量标准研究.《医药导报》.2008,第27卷(第11期),1399-1400. * |
曲婷丽等.参苓白术颗粒的薄层色谱鉴别方法研究.《中成药》.2008,第30卷(第12期),附4. * |
郑小平等.龙胆泻肝片的薄层鉴别方法.《中国药业》.2008,第17卷(第16期),39. * |
Also Published As
Publication number | Publication date |
---|---|
CN101829216A (zh) | 2010-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101829216B (zh) | 一种治疗支气管炎,支气管哮喘的中药制剂制备方法及检测方法 | |
WO2008019588A1 (fr) | Préparation de médecine chinoise traitant la dépression et la neurasthénie; et son procédé d'élaboration | |
WO2007012276A1 (fr) | Médicament destiné au sevrage de la dépendance aux drogues et procédé relatif à celui-ci | |
CN101274025A (zh) | 一种具有清热泻火解毒作用的中药组合物及其制备方法和质量控制方法 | |
CN102641326A (zh) | 一种黄芪提取物及其制备和应用方法 | |
CN102120015A (zh) | 一种用于舒肝解郁、安神定志的中药及制法和质量标准 | |
CN101496870B (zh) | 一种止咳化痰的中药组合物的检测方法 | |
CN100525809C (zh) | 由黄芪、红景天和菝葜制成的药物组合物及其制备方法 | |
CN101396486B (zh) | 治疗咳喘病的中药组合物及其制备方法和质量控制方法 | |
CN102861255B (zh) | 一种治疗流感的药物及其制剂的制备方法及质量控制方法 | |
CN1895438B (zh) | 一种治疗头痛的中药组合物及其制备方法 | |
CN102920964B (zh) | 一种治疗咳嗽的中药制剂 | |
CN1957999B (zh) | 一种中药组合物及其制备方法和检测方法 | |
CN101890087A (zh) | 含有黄连、大黄、黄芩的组合物 | |
CN107102093B (zh) | 复方丹茵膏的检测方法 | |
CN102908519B (zh) | 一种治疗流感的药物及其制剂的制备方法及质量检测方法 | |
CN101108228A (zh) | 一种药物组合物及其制备方法 | |
CN1879850A (zh) | 仙蟾胶囊及其制备方法、质量控制方法 | |
CN101195007A (zh) | 一种治疗感冒咳嗽的药物及其制剂的制备方法及质量控制方法 | |
CN101816749A (zh) | 治疗癃闭的药物及其制法和质量控制方法 | |
CN101670088B (zh) | 一种治疗急、慢性支气管炎的中药组合物 | |
CN102225144B (zh) | 治疗咳喘病的中药组合物及其制备方法 | |
CN101933996A (zh) | 一种具有清热泻火解毒作用的中药组合物及其制备方法和检测方法 | |
CN107014945B (zh) | 一种治疗急性传染性肝炎的中药制剂的检测方法 | |
CN101422588A (zh) | 一种治疗妇科疾病药物的质量控制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG MINGREN FURUIDA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LING PEIXUE Effective date: 20120309 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 250104 JINAN, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120309 Address after: 250104 Ji'nan hi tech District Road No. 3333 Patentee after: Shandong Mingren Furuida Pharmaceutical Co.,Ltd Address before: Xinluo Avenue high tech Zone of Ji'nan City, Shandong Province, No. 989 250101 Patentee before: Ling Peixue |
|
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Ling Inventor after: Ling Peixue Inventor before: Zhang Ling Inventor before: Ling Peixue Inventor before: Liu Yanyan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG LING LING PEIXUE LIU YANYAN TO: ZHANG LING LING PEIXUE |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Hi tech District Ji'nan city Shandong province 250104 Road No. 3333 Patentee after: Shandong Mingren Furuida Pharmaceutical Co., Ltd. Address before: Hi tech District Ji'nan city Shandong province 250104 Road No. 3333 Patentee before: Shandong Mingren Furuida Pharmaceutical Co.,Ltd |